Related Experiment Video
Updated: Jan 6, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Pregnant Women Infected with HIV-1: Real-Life Use
Antoine Bachelard1, Zélie Julia1,2,3,4,5,6,7, Florence Damond2,3
1Assistance Publique-Hôpitaux de Paris.Nord, site Bichat-Claude Bernard, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Nord Val de Seine, Paris, France.
Abstract:
Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) is a convenient, well-tolerated, once-daily, and single-tablet regimen. There are few data on its use during pregnancy. The primary objective was to evaluate the efficacy of BIC/FTC/TAF at delivery, defined as a plasma viral load <50 cp/mL. We conducted a retroprospective, single-center study including pregnant women living with HIV-1 who were on BIC/FTC/TAF. From January 2020 to January 2023, 12 women living with HIV-1 received BIC/FTC/TAF during pregnancy and at delivery. Two were receiving BIC/FTC/TAF at conception and remained on the same combination antiretroviral therapy (cART) throughout the pregnancy, and 10 received BIC/FTC/TAF at least during the third trimester and at delivery. Ten had a plasma viral load <50 cp/mL at delivery. The two who were not suppressed at delivery reported nonadherence to BIC/FTC/TAF, which was not related to treatment side effects. Reported tolerance was good. BIC/FTC/TAF might be a good option during pregnancy and particularly to simplify previous cART but it is necessary to counsel patients to ensure good adherence to this one.
Related Concept Videos
Teratogenicity
Retrovirus Life Cycles
Pharmacokinetics in Pediatric Patients: Drug Excretion
Retroviruses

